Avience Biomedicals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹110(52.88%)
Premium (ELP)
The public market debut of Avience Biomedicals Limited's was completed on Jun 25, 2026 with its listing on the NSE exchange. The IPO process raised 14,53,800 Shares in total capital, consisting of 14,53,800 Shares in new equity.
The offering featured a price range of ₹196 to ₹208 and minimum application size of 600 shares. Investor response during the subscription period from Jun 18, 2026 to Jun 22, 2026 influenced the final allotment ratios across investor categories.
Final allotment was announced on Jun 23, 2026, distributing shares to successful subscribers. The listing established a continuous market for the company's shares, enabling liquidity, valuation transparency, and broader investor participation.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in June 2024, Avience Biomedicals Limited is an ISO-certified company engaged in the manufacturing, supply, and export of molecular diagnostic solutions for the biotechnology, genomics, and in-vitro diagnostics (IVD) sectors. The company offers a wide range of healthcare products, including rapid test kits, molecular diagnostic kits, biochemistry and hematology analyzers, medical devices, and diagnostic reagents. Its products serve pathology laboratories, hospitals, microbiology labs, and research centers in India and overseas. Along with manufacturing, the company also operates as a distributor and trader of medical equipment. Its manufacturing facility is located in Noida, Uttar Pradesh. As of January 31, 2026, Avience Biomedicals had 75 permanent employees and 33 contractual employees.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Diversified Diagnostic Product Portfolio : Offers rapid test kits, analyzers, molecular diagnostics, and medical devices across multiple healthcare segments.
- Strong Distribution Network & Market Reach : Presence across India with growing international footprint supports business expansion.
- Quality-Focused Operations : ISO-certified processes and regulatory compliance enhance product reliability and customer trust.
- Limited Operating History : Recently incorporated company with a relatively short track record.
- Regulatory Compliance Risk : Medical devices and diagnostic products are subject to stringent approvals and regulations.
- Dependence on Healthcare Industry Demand : Growth depends on spending by hospitals, laboratories, and healthcare institutions.
- Mr. Dharam Deo Choudhary
- Mr. Ram Nagina Choudhary
- Mr. Janardan Pal
- Ms. Deepa Choudhary
Avience Biomedicals Limited
Skyline Financial Services Private Limited